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Abstract 1 
Word Count:  75 words 2 
We reviewed almost 300,000 clinical E. coli urine isolates (2009-2013) from 127 facilities to 3 
assess antibiotic resistance among Veterans Affairs healthcare system patients using Clinical 4 
Laboratory Standards Institute and Centers for Disease Control and Prevention National 5 
Healthcare Safety Network definitions/guidance.  Resistance to fluoroquinolones and 6 
trimethoprim/sulfamethoxazole approached 30%.  Resistance to nitrofurantoin, anti-pseudomonal 7 
penicillin/beta-lactamase inhibitors, and carbapenems remained less than 10%.  The percentage 8 
of isolates that were considered multidrug-resistant varied (4.1% to 36.5%) depending on 9 
definition used. 10 
  11 
 3 
Word Count: 996 words 1 
Escherichia coli is the most clinically relevant and multiply-drug resistant bacterial pathogen 2 
causing urinary tract infections (UTI).(1, 2)  Monitoring resistance is important to support clinical 3 
decision-making and public health safety.  The Clinical Laboratory Standards Institute (CLSI) 4 
guidelines for clinical laboratories provide standardized methodology in the preparation and 5 
presentation of cumulative susceptibility data through use of an antibiogram.(3-5) Data from 6 
Centers for Diseases Control and Prevention (CDC’s) National Healthcare Safety Network 7 
(NHSN), are also of great value for tracking antimicrobial resistance.(6) Limited data are available 8 
to provide a comprehensive description of E. coli resistance nationally in inpatient and outpatient 9 
settings. 10 
 11 
The Veterans Affair’s (VA) is the nation’s largest integrated healthcare system, providing care to 12 
over 9 million Veterans in over 140 medical centers and 1200 outpatient clinics throughout the 13 
United States (US).(7)  Antimicrobial susceptibility data are captured in the VA’s electronic 14 
datasets, and provide a unique opportunity to assess resistance nationally. Our intent is to 15 
describe national antimicrobial resistance rates in clinical E. coli urine isolates and to highlight 16 
differences in resistance rates using CLSI and NHSN criteria. 17 
 18 
We retrospectively evaluated adult (age >18 years) VA patients with urine cultures growing E. coli 19 
between January 2009 to December 2013.  We utilized three different criteria for assessing 20 
resistance:  CDC’s NHSN criteria which captures the first isolate per-patient per-month;(8) CLSI 21 
guidance which recommends including only the first isolate per-patient per-year for antibiogram 22 
presentation;(3, 5)  and a third method using the most resistant isolate per-person per-facility per-23 
year since the first two approaches may underestimate overall resistance rates.(9) We removed 24 
all same day duplicate antibiotic susceptibility test results (same patient, same isolate, same day) 25 
keeping the most resistant result.(8, 10) 26 
 4 
 1 
To classify antibiotic resistance rates, individual antibiotic agents were further categorized based 2 
on international standard definitions of the European Centre for Disease Prevention and Control 3 
(ECDC) and the CDC for Enterobacteriaceae and the CDC’s Antibiotic Resistance Patient Safety 4 
Atlas (AR Atlas) E. coli phenotype definitions.(11, 12)  The CDC’s AR Atlas includes data on 5 
healthcare-associated infections reported to the CDC’s NHSN. Multidrug-resistance (MDR) was 6 
defined as non-susceptibility to at least one drug in at least 3 categories, using the ECDC/CDC 7 
international standard and the CDC’s AR Atlas definitions.(11, 12)   8 
 9 
During the 5-year study, 297,046 E. coli isolates were identified from 127 sites in all 9 CDC regions 10 
using the NHSN methods (first isolate per month).  Most isolates were obtained from white 11 
(74.8%) males (77.8%) in the outpatient setting (76.4%).  Resistance was 34.3% for 12 
fluoroquinolones, 28.2% for trimethoprim/sulfamethoxazole, and under 10% for extended 13 
spectrum cephalosporins (6.9%), nitrofurantoin (6.2%), anti-pseudomonal penicillin/beta-14 
lactamase inhibitors (5.3%), and carbapenems (0.4%; Table 1).  Resistance rates were higher 15 
for inpatient versus outpatient isolates for all antibiotic categories assessed (Table 2) and varied 16 
by CDC region and treatment setting (Figures 1 and 2).   17 
 18 
We identified 297,046 E. coli isolates when we included only the first (per CLSI recommendations) 19 
or most resistant isolate per patient per facility per year (Table 1).  Resistance rates were similar 20 
with both methods (first isolate vs. most resistant).   21 
 22 
In a sub-analysis, we overlaid the two different global MDR definitions. (11, 12)  The percentage 23 
of MDR isolates was 36.5% (108,500/297,046) using the ECDC/CDC international standard and 24 
4.1% (12,293/297,046) using the CDC’s AR Atlas definitions. We further classified the prevalence 25 
of MDR for inpatient and outpatient isolates using both methods (ECDC/CDC: 46.6% and 33.4%, 26 
 5 
CDC AR Atlas: 7.2% and 3.2%, respectively).   1 
 2 
Antimicrobial resistance among E. coli urinary isolates is increasing in the US.(6, 13)  Confusion 3 
exists when local facilities compare their CLSI-based antibiogram with national surveillance data.  4 
We identified high rates of antimicrobial resistance to several commonly used E. coli UTI 5 
treatment options.  The overall rate of fluoroquinolone resistance using NHSN methods was 6 
34.3%, with resistance reaching almost 50% among inpatients and 30% for outpatients similar to 7 
previous findings.(6, 13-16) These findings are concerning as fluoroquinolones are frequently 8 
used empirically to treat UTIs, especially complicated infections.   9 
 10 
Our study also demonstrated trimethoprim/sulfamethoxazole resistance approaching 30%.  11 
Several studies, including E. coli urinary isolates from US outpatients, have reported greater than 12 
20% resistance to trimethoprim/sulfamethoxazole.(15, 16) Trimethoprim/sulfamethoxazole 13 
should not be used for empiric treatment of acute cystitis when local antibiograms reveal 20% or 14 
greater resistance according to Infectious Diseases Society of America (IDSA) guidelines.(2)  15 
Similar to previous findings, we demonstrated that resistance to nitrofurantoin continues to remain 16 
low and this may be an appropriate option for patients with uncomplicated cystitis.(15, 16)  For 17 
empiric inpatient treatment options, our data suggests that anti-pseudomonal penicillin/beta-18 
lactamase inhibitors and carbapenems remain among the most active agents, similar to recent 19 
nationwide surveillance data.(6, 13)   20 
 21 
We found vast differences in the number of isolates considered MDR depending on the definition 22 
used. According to the CDC’s AR Atlas definition, 7.2% of our inpatient isolates were MDR.  23 
Similarly, 5.5-8.1% of E. coli causing a CAUTI reported to the CDC’s NHSN from 2011 to 2014 24 
were MDR.(6)  Using the international standard MDR definition, over 45% and 30% of inpatient 25 
and outpatient isolates, respectively, were considered MDR. Our results suggest these definitions 26 
 6 
may overestimate resistance compared to the methods used by the CDC AR Atlas. 1 
 2 
There are several limitations to our study.  We did not distinguish colonization versus true 3 
symptomatic infection. Our data represents all positive microbiologic E. coli urine cultures and 4 
thus represents the full ecological resistance among all cultures in the VA system. The 5 
heterogeneity among VA microbiology laboratories and the antibiotics tested also impacts our 6 
data.  The CLSI MIC susceptibility breakpoints for Enterobacteriaceae have changed over time, 7 
and these changes may have been applied at different times by individual laboratories. As such, 8 
we applied the 2014 CLSI breakpoints to our data when MIC data was available.  Finally, the 9 
generalizability of our results may be limited to the VA population. 10 
 11 
In conclusion, among almost 300,000 urinary E. coli isolates collected from a predominately male 12 
VA outpatient population, resistance to fluoroquinolones and trimethoprim/sulfamethoxazole 13 
approached 30%.  Resistance to extended-spectrum cephalosporins, nitrofurantoin, anti-14 
pseudomonal penicillin/beta-lactamase inhibitors, and carbapenems remained low.  Of note, the 15 
percentage of isolates that considered MDR varied considerably depending on definition used. 16 
  17 
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Table 1. Escherichia coli Antibiotic Resistance Among Veterans Affairs Inpatient and 1 
Outpatient Facilities Nationally by Method Used to Describe Rates 2 
Determine Rates (2009-2013) 3 
  4 
Antibiotic Category 
(NHSN Methods) 
 
First Isolate Per 
Patient Per Facility 
Per Month 
(CLSI Methods) 
 
First Isolate Per 
Patient Per Facility 
Per Year) 
Most Resistant 
Isolate Per Patient 
Per Facility Per Year 
Aminoglycoside 12.6 (296,022) 10.9 (243,577) 11.5 (243,590) 
Antipseudomonal 
penicillin/ beta-lactamase 
inhibitor 5.3 (206,707) 4.7 (170,013) 5.5 (170,342) 
Carbapenem 0.4 (231,153) 0.4 (189,809) 0.4 (190,017) 
Extended spectrum 
cephalosporin 6.9 (264,519) 6.0 (217,513) 6.5 (217,886) 
Fluoroquinolone 34.3 (291,674) 29.5 (240,005) 30.4 (240,086) 
Nitrofurantoin 6.2 (249,096) 5.4 (204,526) 6.1 (204,611) 
Amoxicillin or ampicillin/ 
beta-lactamase inhibitor 39.6 (238,738) 37.2 (196,203) 39.0 (196,450) 
Trimethoprim/ 
sulfamethoxazole 28.2 (296,501) 25.2 (243,957) 26.3 (243,982) 
Total Number of Isolates  297,046 244,411 244,411 
CDC= Centers for Disease Control and Prevention; CLSI= Clinical and Laboratory Standards 5 
Institute; NHSN= National Healthcare Safety Network 6 
 7 
 11 
Data are % non-susceptible (number of isolates tested)  1 
 2 
Aminoglycoside category included amikacin, gentamicin, and tobramycin. 3 
Antipseudomonal penicillin/ beta-lactamase inhibitor category included piperacillin/tazobactam 4 
and ticarcillin/clavulanic acid. 5 
Carbapenem category included imipenem, meropenem, doripenem, and ertapenem. 6 
Extended spectrum cephalosporin category included ceftriaxone, ceftazidime, cefotaxime, and 7 
cefepime. 8 
Fluoroquinolone category included levofloxacin and ciprofloxacin. 9 
Amoxicillin or ampicillin/ beta-lactamase inhibitor category included amoxicillin/clavulanic acid 10 
and ampicillin/sulbactam. 11 
  12 
 12 
Table 2. Escherichia coli Antibiotic Resistance Among Veterans Affairs Inpatient and 1 
Outpatient Facilities Nationally by Healthcare Setting (2009-2013)* 2 
  3 
 Healthcare Setting 
Antibiotic Category Overall Inpatient Outpatient 
Aminoglycoside 
12.6 
(296,022) 
17.4 
(69,824) 
11.1 
(226,198) 
Antipseudomonal penicillin/beta-lactamase 
inhibitor 
5.3  
(206,707) 
8.0  
(50,795) 
4.5 
(155,912) 
Carbapenems 
0.4  
(231,153) 
0.5 
(55,643) 
0.4 
(175,510) 
Extended-spectrum cephalosporin 
6.9 
 (264,519) 
11.3 
(63,706) 
5.4 
(200,813) 
Fluoroquinolones 
34.3 
(291,674) 
46.5 
(68,659) 
30.5 
(223,015) 
Nitrofurantoin 
6.2  
(249,096) 
7.0  
(56,025) 
6.0  
(193,071) 
Amoxicillin or ampicillin/beta-lactamase 
inhibitor 
39.6 
(238,738) 
47.7 
(56,168) 
37.0 
(182,570) 
Trimethoprim/sulfamethoxazole 
28.2 
(296,501) 
35.6 
(69,958) 
26.0 
(226,543) 
Total Number of Isolates 297,046 70,101 226,945 
Results by healthcare setting include the first Isolate per patient per facility per month (CDC NHSN 4 
Methods)* 5 
 6 
 13 
CDC= Centers for Disease Control and Prevention; CLSI= Clinical and Laboratory Standards 1 
Institute; NHSN= National Healthcare Safety Network 2 
 3 
Data are % non-susceptible (number of isolates tested)  4 
 5 
Aminoglycoside category included amikacin, gentamicin, and tobramycin. 6 
Antipseudomonal penicillin/ beta-lactamase inhibitor category included piperacillin/tazobactam 7 
and ticarcillin/clavulanic acid. 8 
Carbapenem category included imipenem, meropenem, doripenem, and ertapenem. 9 
Extended spectrum cephalosporin category included ceftriaxone, ceftazidime, cefotaxime, and 10 
cefepime. 11 
Fluoroquinolone category included levofloxacin and ciprofloxacin. 12 
Amoxicillin or ampicillin/ beta-lacamase/beta-lactamase inhibitor category included 13 
amoxicillin/clavulanic acid and ampicillin/sulbactam. 14 
 15 
 14 
Figure 1.  Escherichia coli Antibiotic Resistance Among Veterans Affairs Inpatient Facilities Nationally by CDC Region (2009-1 
2013)* 2 
 3 
Results by CDC region include the first Isolate per patient per facility per month (CDC NHSN Methods)* 4 
 5 
 6 
CDC= Centers for Disease Control and Prevention; E N Central= East North Central Region; E S Central= East South Central Region; 7 
ES Ceph= Extended spectrum cephalosporin; FQ= Fluoroquinolone; Mid Atlantic= Middle Atlantic Region; Mountain=Mountain Region; 8 
New England= New England Region; Pacific= Pacific Region; S Atlantic= South Atlantic Region; W N Central= West North Central Region; 9 
W S Central= West South Central Region 10 
 11 
Data are % non-susceptible (total number of isolates tested). Not every antibiotic category tested for every isolate tested.  12 
 13 
Carbapenem category included imipenem, meropenem, doripenem, and ertapenem. 14 
Extended-spectrum cephalosporin category included ceftriaxone, ceftazidime, cefotaxime, and cefepime. 15 
Fluoroquinolone category included levofloxacin and ciprofloxacin.  16 
 15 
Figure 2.  Escherichia coli Antibiotic Resistance Among Veterans Affairs Outpatient Facilities Nationally by CDC Region (2009-1 
2013)* 2 
 3 
Results by CDC region include the first Isolate per patient per facility per month (CDC NHSN Methods)* 4 
 5 
 6 
CDC= Centers for Disease Control and Prevention; E N Central= East North Central Region; E S Central= East South Central Region; 7 
ES Ceph= Extended spectrum cephalosporin; FQ= Fluoroquinolone; Mid Atlantic= Middle Atlantic Region; Mountain=Mountain Region; 8 
New England= New England Region; Pacific= Pacific Region; S Atlantic= South Atlantic Region; W N Central= West North Central Region; 9 
W S Central= West South Central Region 10 
 11 
Data are % non-susceptible (total number of isolates tested). Not every antibiotic category tested for every isolate tested.  12 
 13 
Carbapenem category included imipenem, meropenem, doripenem, and ertapenem. 14 
Extended-spectrum cephalosporin category included ceftriaxone, ceftazidime, cefotaxime, and cefepime. 15 
Fluoroquinolone category included levofloxacin and ciprofloxacin. 16 
